Secondary Ischemic Stroke Prevention

被引:19
作者
Bangad, Aaron [1 ]
Abbasi, Mehdi [1 ]
de Havenon, Adam [1 ]
机构
[1] Yale Univ, Dept Neurol, 15 York St, New Haven, CT 06510 USA
关键词
Stroke; Randomized clinical trial; Secondary stroke prevention; HEALTH-CARE PROFESSIONALS; HIGH-RISK PATIENTS; BLOOD-PRESSURE; ATRIAL-FIBRILLATION; RECURRENT STROKE; PHYSICAL-ACTIVITY; VASCULAR EVENTS; EMBOLIC STROKE; DIETARY-SODIUM; OPEN-LABEL;
D O I
10.1007/s13311-023-01352-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The health burden of ischemic stroke is high and will continue to increase with an aging population. Recurrent ischemic stroke is increasingly recognized as a major public health concern with potentially debilitating sequelae. Thus, it is imperative to develop and implement effective strategies for stroke prevention. When considering secondary ischemic stroke prevention, it is important to consider the mechanism of the first stroke and the related vascular risk factors. Secondary ischemic stroke prevention typically includes multiple medical and, potentially, surgical treatments, but with the shared goal of reducing the risk of recurrent ischemic stroke. Providers, health care systems, and insurers also need to consider the availability of treatments, their cost and patient burden, methods for improving adherence, and interventions that target lifestyle risk factors such as diet or activity. In this article, we discuss aspects from the 2021 AHA Guideline on Secondary Stroke Prevention as well as highlight additional information relevant to best practices for reducing recurrent stroke risk.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 113 条
  • [1] Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
    Amarenco, Pierre
    Benavente, Oscar
    Goldstein, Larry B.
    Callahan, Alfred, III
    Sillesen, Henrik
    Hennerici, Michael G.
    Gilbert, Steve
    Rudolph, Amy E.
    Simunovic, Lisa
    Zivin, Justin A.
    Welch, K. Michael A.
    [J]. STROKE, 2009, 40 (04) : 1405 - 1409
  • [2] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [3] [Anonymous], 1987, LANCET, V2, P1351
  • [4] [Anonymous], 1993, Stroke, V24, P543
  • [5] Antiplatelet Trialists' Collaboration, 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
  • [6] Prediction of Early Recurrence After Acute Ischemic Stroke
    Arsava, E. Murat
    Kim, Gyeong-Moon
    Oliveira-Filho, Jamary
    Gungor, Levent
    Noh, Hyun Jin
    Lordelo, Morgana de Jesus
    Avery, Ross
    Maier, Ilko L.
    Ay, Hakan
    [J]. JAMA NEUROLOGY, 2016, 73 (04) : 396 - 401
  • [7] Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
    Bath, Philip M.
    Woodhouse, Lisa J.
    Appleton, Jason P.
    Beridze, Maia
    Christensen, Hanne
    Dineen, Robert A.
    Duley, Lelia
    England, Timothy J.
    Flaherty, Katie
    Havard, Diane
    Heptinstall, Stan
    James, Marilyn
    Krishnan, Kailash
    Markus, Hugh S.
    Montgomery, Alan A.
    Pocock, Stuart J.
    Randall, Marc
    Ranta, Annemarei
    Robinson, Thompson G.
    Scutt, Polly
    Venables, Graham S.
    Sprigg, Nikola
    [J]. LANCET, 2018, 391 (10123) : 850 - 859
  • [8] Impact of the Ageing Population on the Burden of Stroke: The Dijon Stroke Registry
    Bejot, Yannick
    Bailly, Henri
    Graber, Mathilde
    Garnier, Lucie
    Laville, Annabel
    Dubourget, Lucile
    Mielle, Nathalie
    Chevalier, Corinne
    Durier, Jerome
    Giroud, Maurice
    [J]. NEUROEPIDEMIOLOGY, 2019, 52 (1-2) : 78 - 85
  • [9] Benavente OR, 2013, LANCET, V382, P506
  • [10] Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
    Benavente, Oscar R.
    Hart, Robert G.
    McClure, Leslie A.
    Szychowski, Jeffrey M.
    Coffey, Christopher S.
    Pearce, Lesly A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) : 817 - 825